Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Overview: Amgen is a global biotechnology company operating in a single segment: human therapeutics. The company focuses on supportive cancer care, nephrology, and inflammation. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL. The reporting period was significantly impacted by regulatory and reimbursement challenges regarding Erythropoiesis-Stimulating Agents (ESAs), specifically Aranesp and EPOGEN, as well as a major restructuring plan initiated in 2007.
Key Financial Metrics
| Metric | 2008 | 2007 | 2006 |
|---|---|---|---|
| Total Revenues | $15.0 billion | $14.8 billion | $14.3 billion |
| Product Sales | $14.7 billion | $14.3 billion | $13.9 billion |
| Net Income | $4.2 billion | $3.2 billion | $3.0 billion |
| Diluted EPS | $3.90 | $2.82 | $2.48 |
| Operating Cash Flow | $6.0 billion | $5.4 billion | $5.4 billion |
| Total Debt | $10.2 billion | $11.2 billion | $9.0 billion |
| Cash & Marketable Securities | $9.6 billion | $7.2 billion | $6.8 billion |
Note: The filing text does not provide a specific "Gross Margin" percentage, but Cost of Sales was $2.3 billion in 2008 (16% of product sales) compared to $2.5 billion in 2007 (18% of product sales).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 2% to $15.0 billion. Product sales grew 3% to $14.7 billion. This growth was driven by ENBREL (+11%) and Neulasta/NEUPOGEN (+9%), which offset a significant decline in Aranesp sales (-13%).
- Product Performance:
- Aranesp: Sales dropped to $3.1 billion (from $3.6 billion) due to regulatory labeling changes and CMS reimbursement restrictions in the U.S. supportive cancer care setting.
- ENBREL: Sales rose to $3.6 billion, aided by a distribution model change and price increases, despite competitive share loss.
- EPOGEN: Sales remained relatively flat at $2.5 billion, impacted by CMS Erythropoietin Monitoring Policy (EMP) changes reducing dosing.
- Restructuring Charges: The company incurred $148 million in restructuring charges in 2008 (compared to $739 million in 2007). Total estimated charges for the plan increased to $950–$985 million, with $887 million incurred through year-end 2008.
- Legal Settlements: Recorded $288 million in "Other charges" in 2008, primarily for the settlement of the Ortho Biotech antitrust litigation.
- Debt Management: Repaid $2.0 billion of floating rate notes in 2008. Issued $1.0 billion in new long-term notes (2018 and 2038 maturities).
Guidance, Outlook, and Risks
- Regulatory Risks (ESAs): Continued challenges for Aranesp and EPOGEN due to safety concerns. The FDA is reviewing a Risk Evaluation and Mitigation Strategy (REMS) for ESAs, which could materially impact future sales. Labeling changes restrict use in curative cancer settings and limit hemoglobin targets.
- Reimbursement Risks: CMS implemented a bundled payment system for dialysis services starting in 2011, which may negatively impact EPOGEN and Aranesp sales. Cost containment pressures from private payors are also increasing.
- Competition: Increased competition from biosimilars in Europe for Aranesp, Neulasta, and NEUPOGEN. ENBREL faces competition from new products like HUMIRA and REMICADE.
- Outlook: Management expects continued growth in ENBREL and Neulasta/NEUPOGEN. Future Aranesp sales remain uncertain due to regulatory and reimbursement developments. The company is focused on launching new products, specifically denosumab (osteoporosis) and Nplate (thrombocytopenia).
- Restructuring: The company expects to incur remaining restructuring costs in 2009. The plan aims to improve cost structure while maintaining R&D investment.
Key Facts for Investor Verification
- ESA Regulatory Status: Verify the final status of the FDA-mandated REMS program for ESAs and any further CMS reimbursement policy changes for 2009.
- Restructuring Completion: Confirm the timing and total cost of the remaining restructuring charges expected in 2009 (estimated $63–$98 million remaining).
- Product Pipeline: Monitor the FDA review timeline for denosumab (PDUFA date October 2009) and the commercial launch of Nplate.
- Legal Contingencies: Track the status of ongoing litigation, including the Roche patent infringement case (permanent injunction granted but appealed) and the Average Wholesale Price (AWP) class action settlements.
- Debt Maturities: Note the $1.0 billion debt maturity in November 2009 and the company's liquidity position to service this debt.